The development of immune-checkpoint inhibitors (ICIs) has heralded a new era in cancer
treatment, enabling the possibility of long-term survival in patients with metastatic disease …

Immunotherapy using immune-checkpoint modulators revolutionizes the oncology field far
beyond their remarkable clinical efficacy in some patients. It creates radical changes in the …

The next decade in cancer therapy will be marked by the expansion of immunotherapies,
namely immune checkpoint inhibitors. The increasing number and combination of …

Immune-checkpoint inhibitors (ICIs) have dramatically changed the management of
advanced cancers. Designed to enhance the antitumour immune response, they can also …

Tumor cells predominantly express self-antigens and overcoming self-tolerance is the
primary challenge to effective immunotherapy. Tumors also express ligands for co-inhibitory …

Immune checkpoint inhibitors are reshaping the prognosis of many cancer and are
progressively becoming the standard of care in the treatment of many tumour types …

Cancer immunotherapy has transformed the treatment of cancer. However, increasing use of
immune-based therapies, including the widely used class of agents known as immune …

Purpose of review Immune checkpoint inhibitors have revolutionised the treatment of
multiple malignancies and have a growing list of indications. As our familiarity with these …

Immunotherapy by checkpoint inhibition is about to profoundly change cancer therapy. The
number of indications are growing at an unprecedented speed. Clinical studies have …

Immune checkpoint inhibitors (ICI) have emerged as a remarkable treatment option for
diverse cancer types. Currently, ICIs are approved for an expanding array of cancer …